Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2020
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosisBruce Ac Cree, Baldur Magnusson, Nicolas Rouyrre, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2022
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 yearsBruce Ac Cree, Douglas L Arnold, Robert J Fox, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2018
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II studyJeffrey A Cohen, Giancarlo Comi, Douglas L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 9, 2022
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trialDouglas L Arnold, Daniela Piani-Meier, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2022
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trialBruce Ac Cree, Krzysztof W Selmaj, Lawrence Steinman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2023
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trialRobert T Naismith, Jeffrey A Cohen, Amit Bar-Or, et al.
JCI Insight|February 13, 2019
Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosisAriele L Greenfield, Ravi Dandekar, Akshaya Ramesh, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2025
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trialsJeffrey A Cohen, Douglas L Arnold, John DeLuca, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 16, 2015
Placebo-controlled study in neuromyelitis optica-Ethical and design considerationsBruce Ac Cree, Jeffrey L Bennett, Mark Sheehan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2024
Choroid plexus volume differentiates MS from its mimicsElle Levit, Zheng Ren, Virgilio Gonzenbach, et al.
Pageof 4